Comparative Pharmacology
Head-to-head clinical analysis: CELLCEPT versus SIROLIMUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELLCEPT versus SIROLIMUS.
CELLCEPT vs SIROLIMUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.
Sirolimus is an immunosuppressant that forms a complex with FKBP12, which inhibits the mechanistic target of rapamycin (mTOR), a key regulator of cell cycle progression and proliferation. This inhibition blocks signal transduction from cytokine and growth factor receptors, thereby suppressing T-cell activation and proliferation.
Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.
Loading dose of 6 mg orally on day 1, followed by 2 mg orally once daily; or 3 mg orally on day 1, followed by 1 mg orally once daily. Maintenance dosing adjusted to achieve trough concentrations of 4-20 ng/mL. For de novo renal transplant recipients: 6 mg loading dose then 2 mg/day.
None Documented
None Documented
Clinical Note
moderateSirolimus + Digoxin
"Sirolimus may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTemsirolimus + Digoxin
"Temsirolimus may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateSirolimus + Digitoxin
"Sirolimus may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTemsirolimus + Digitoxin
"Temsirolimus may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life of MPA is approximately 17.9 ± 6.5 hours in renal transplant patients. Clinical significance: dosing interval of 12 hours maintains therapeutic levels.
Terminal half-life approximately 57-63 hours in adults, allowing once-daily dosing; longer in hepatic impairment.
Mycophenolic acid (MPA) is primarily excreted in urine as mycophenolic acid glucuronide (MPAG) (87% of dose); <1% excreted as unchanged MPA. Fecal excretion accounts for approximately 6% of dose.
Primarily fecal (91%) with minimal renal excretion (2.2% as metabolites).
Category C
Category D/X
Immunosuppressant
Immunosuppressant